Omeros (OMER) delivered a decisive beat in the third quarter, reporting non-GAAP earnings of $0.06 per share against a consensus estimate of a $0.05 loss, a 220.0% surprise. Revenue of $35.93 million topped the $30.9 million consensus by 16.3%, and earnings grew 131.6% year over year. Yartemlea, the first approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), is now carrying the company. Operating income turned positive at $4.5 million, up from $0.1 million in the second quarter, and operating cash flow reached $13.3 million. That is the central development: Omeros is running cash-flow positive well ahead of its original 2027 target. The central tension is that the launch is moving from its explosive phase into a grind. Sequential growth is slowing, discounts are rising, and the European opportunity is effectively gone.
The quality of the beat deserves scrutiny on two fronts. First, GAAP results look nothing like the adjusted figure. Omeros posted a GAAP net loss of $57.4 million, or $0.79 per share, driven by a $62.0 million non-cash mark-to-market loss on the derivative embedded in its 2029 convertible notes. The derivative's value rises with the share price, so this charge is a byproduct of stock strength rather than operating weakness. It does, however, guarantee continued GAAP volatility. Second, the company's non-GAAP measure strips out only that remeasurement. The $4.7 million adjusted profit therefore still includes $6.5 million of income from discontinued operations and a $1.9 million loss on note extinguishment. On a continuing-operations basis excluding the derivative, results were roughly breakeven to slightly negative. The operating trajectory is real, but the headline profit is thinner than it appears.
Beneath the numbers, adoption metrics remain strong. Net sales climbed from $9.9 million in the first quarter to $28.5 million in the second and $35.9 million in the third. Ordering accounts rose to 109 from 73 in the prior quarter and 30 in the first quarter. Formulary (P&T) approvals reached 80% of the top 40 transplant centers, up from roughly 55-60% last quarter. Still, quarter-over-quarter net sales growth slowed to 26% from 188% in the second quarter. Gross-to-net deductions widened to 14% from 11.5% as 340B purchases increased, and management guided that figure toward the high teens. Management frames the shift as intentional, reflecting broader customer reach and more outpatient use, and that is credible. Even so, it means gross demand will need to outrun rising discounts. Operating expenses also rose to $30.6 million from $27.7 million as Omeros added 10 field education roles, including a six-person nurse educator team.
The U.S. reimbursement setup improved meaningfully. NTAP status took effect October 1, providing up to $287,079 in additional Medicare payment per eligible inpatient case. Management also highlighted that Yartemlea's pass-through status, which runs through June 2029, shields it from the 340B payment cut scheduled for 2027. That cut hits branded C5 inhibitors used off-label. Management said revenue growth has continued into the fourth quarter, though it still offers no revenue guidance. Patient-level and vial data also remain undisclosed. The risks are concrete. The CHMP upheld its negative opinion on re-examination, effectively closing the EU path, and compassionate use is closing to new patients. The OMS527 cocaine use disorder trial slipped to early 2027. On the call, management said cash fell from about $132 million to $95.3 million after the $60.2 million convertible repurchase. That buyback cut potential conversion shares by 4.9 million and trimmed cash interest, but it consumed a meaningful share of liquidity. Up to $100 million in near-term Novo milestones tied to zaltenibart offers a potential offset.
Investor sentiment shifted sharply ahead of the report, rising from 0.13 to 0.56, a substantial move from barely positive to solidly positive. Price action has been less enthusiastic. Shares were trading at $17.49 entering the release, just 5.0% above the open following the August report. That leaves them 17.7% below the 52-week high of $21.24 set September 22 and 10.4% above the October 16 low of $15.85, which came in the month of the CHMP setback. The stock remains 27.1% above its 200-day moving average. Overall, the market has rewarded the launch but has already given back a large part of its late-summer run.
The bottom line is that Omeros delivered the quarter launch bulls wanted: a clean revenue beat, positive operating income, real cash generation, and a strengthened U.S. reimbursement position. Bears still have legitimate ammunition, however. Sequential growth is decelerating, gross-to-net is heading higher, Europe is lost, and the adjusted profit leans on items outside continuing operations. With sentiment already much more optimistic, the next leg depends on whether NTAP and 340B tailwinds can keep sales compounding as discounts deepen.